MDxHealth SA MDXH

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
53/100
Moderate

Ranked against 278 peers in Diagnostics & Research

Key strengths

  • Improving FCF Trend FCF trend score is positive (score 0.76). Improving FCF margin signals compounding operational leverage.
  • Conservative Leverage Leverage position is conservative vs peers (score 0.98). Balance sheet flexibility is a strategic asset for serial acquirers.

Key risks

  • Weak Capital Return Profile Capital return quality is below peers (score 0.20). Low ROIC raises questions about M&A discipline and pipeline ROI.
  • Declining Capital Returns ROIC durability is weak (score 0.32). Volatility or decline in returns is a leading moat erosion signal.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
52
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

What the Medical Devices & Diagnostics template measures

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Pricing Power & Consumable Moat

Score 52 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes. An instrument that runs only proprietary reagents or cartridges creates a recurring, high-margin stream a competitor cannot win without displacing the hardware and retraining the staff around it. Sustained premium gross margins are the clearest evidence that the attach rate is real.

R&D Pipeline & Capital Returns

Score 25 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing. This defense pairs it with the returns actually earned on capital already deployed: high, durable returns say the previous generation of R&D and acquisitions produced something that lasted, which is the only real evidence the next round will too.

FCF Quality & Cash Conversion

Score 64 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash. Free cash flow is therefore the more honest measure of what the business earns. Cash flow that consistently exceeds net income indicates the charges are bookkeeping rather than economics.

Commercial Execution

Score 59 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate. Commercial execution is whether that expense is scaling: an operating margin above peers, improving as revenue grows, means the same salesforce is carrying more product rather than the company buying growth.

Capital Structure & Resilience

Score 76 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn. Recurring consumable revenue supports more leverage than one-off equipment sales do — but only up to the point where interest cover and net debt still leave room for the next deal or the next bad year.

Growth Durability

Score 46 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle. Steady revenue growth alongside stable asset productivity suggests placements are compounding, each new instrument adding to a consumable stream that persists, rather than a single approval or tender having temporarily lifted the numbers.

Understanding MDXH's moat

What is MDxHealth SA's moat score?

MDxHealth SA (MDXH) scores 53 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 278 companies in Diagnostics & Research.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 278 companies in Diagnostics & Research. The defenses are then weighted to produce the overall score out of 100.

Why is MDxHealth SA scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for MDxHealth SA?

The Medical Devices & Diagnostics template measures 6 defenses: Pricing Power & Consumable Moat, R&D Pipeline & Capital Returns, FCF Quality & Cash Conversion, Commercial Execution, Capital Structure & Resilience, Growth Durability. Each is scored independently, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

What does the moat score mean for investors?

A moat is a durable structural advantage that lets a company defend its returns from competitors. A high score indicates the financial signature of one — pricing power, cost advantage, customer stickiness — measured relative to peers. It is a quantitative screen built from reported financials, not a price target or a recommendation, and it describes the business rather than the attractiveness of the stock at its current price.

Send Feedback
Please select a category.
0/1000